Venus Remedies share news, announcements and annual reports
NSE: VENUSREMBSE: 526953Pharmaceuticals & BiotechnologySmall Cap
Venus Remedies Limited · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed May 1995 on BSE, Dec 2006 on NSE
Last close ₹1,238.60down ₹50.70 (3.93%)BSE ₹1,231.75
Share price at the NSE close on 30 Oct 2026. Previous close ₹1,289.30.
30 Oct: open ₹1,290.00, high ₹1,319.00, low ₹1,225.10
52-week range of traded prices to 30 Oct 2026
₹432.10Low, 31 Oct 2025₹2,044.30High, 29 Jun 2026
- Under NSE's long-term additional surveillance, stage IV, on the list for 30 Oct 2026. The exchange puts a share here when its price has moved unusually, and trading in it carries extra conditions.
- Delivery only: shares bought must be paid for in full, with no selling on the same day.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹1,656 Cr1,337th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 13.61
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 2.35
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.81%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 18.7%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 21.0%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Sep 2026.
- 0.00
- Volume, NSEVolume. Shares traded on the last trading day. Volume in the glossary
- 48,127
Venus Remedies share news and announcements
697 announcements, routine notices left out, newest first. Page 8 of 14.
Nov 2018
14 Nov · Results
14 Nov · Board meeting
6 Nov · Updates
5 Nov · Updates
Sep 2018
24 Sep · Meeting
Aug 2018
13 Aug · Results
13 Aug · Board meeting
Jun 2018
May 2018
31 May · Legal
Exchange has sought clarification from Venus Remedies Limited with respect to Non-compliance as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results not submitted within 30 minutes from end of board meeting. -2. The company has not submitted the Statement of Modified Opinion or in case of unmodified opinion(s), a declaration to that effect to the Stock Exchange. -3. Consolidated Reconciliation of profit and loss not submitted -4. Consolidated Reconciliation of Equity not submitted The response of the Company is awaited.30 May · Results
28 May · Board meeting
Apr 2018
Feb 2018
12 Feb · Board meeting
12 Feb · Results
Jan 2018
Dec 2017
7 Dec · Board meeting
7 Dec · Results
Nov 2017
Sep 2017
29 Sep · Meeting
1 Sep · Results
1 Sep · Board meeting
Aug 2017
4 Aug · Board meeting
Not held on this date
May 2017
30 May · Results